誠益通(300430.SZ):中標2020年智能製造系統解決方案供應商項目
格隆匯 7 月 29日丨誠益通(300430.SZ)公佈,公司近日收到中招國際招標有限公司出具的《中標通知書》,公司中標2020年智能製造系統解決方案供應商—數字化車間集成-製藥專用設備(招標編號:TC200H01D/分包9)。
自公司成立以來,公司深耕醫藥生物智能製造領域,堅持技術創新,重視研發投入。目前公司建立了較為完備的研發設計體系,取得了多種富有高技術附加值的研究成果。此次中標工信部主辦的2020年智能製造系統解決方案供應商,充分説明了公司在智能製造領域的能力和地位,公司也將以此為契機再接再厲繼續加強研發技術投入提高公司的核心競爭力。
此次中標的獎補金額以實際收到的金額為準,項目中標不影響公司業務的獨立性,同時,也為公司進一步業務拓展打下了重要基礎。項目簽訂正式合同並順利推進後將對公司生產經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.